为什么欧洲医疗技术并购需要监管优先？
欧洲医疗技术企业可能拥有高质量研发、临床证据和渠道能力。对中国买方而言，收购可以带来产品、认证、品牌和欧洲市场入口。
但医疗技术交易必须先看监管和质量体系。如果产品无法维持认证，收入和估值都会受到直接影响。
估值重点
买方应关注CE认证、MDR路径、临床证据、毛利率、渠道结构、售后服务、产品生命周期、研发管线、知识产权和质量体系。
如果销售依赖单一经销商或单一产品，估值应体现集中风险。
尽职调查重点
尽调应覆盖技术文件、临床证据、质量管理体系、召回和投诉记录、经销商合同、产品责任保险、数据隐私、知识产权和库存。
中国买方还应评估产品进入中国或其他亚洲市场的注册路径。
Lyndon如何协助
Lyndon可协助中国买方、欧洲医疗技术企业和顾问准备估值、监管风险清单、资料室和交易执行。
About the Author
Daniel Bae
Co-founder & CEO, Lyndon Advisory
Daniel is an investment banker with 15+ years of experience in M&A, having advised on deals worth over US$30 billion. His career spans Citi, Moelis, Nomura, and ANZ across London, Hong Kong, and Sydney. He holds a combined Commerce/Law degree from the University of New South Wales. Daniel founded Lyndon Advisory to solve the pain points in M&A, enabling bankers to focus on what matters most — delivering trusted advice to clients.
About Lyndon Advisory
Lyndon Advisory is an M&A advisory firm built for Asia Pacific. We help business owners sell their companies and investors make strategic acquisitions with senior-led execution, disciplined process management, and AI-supported buyer intelligence.
Learn about selling your business